[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100540317":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":7,"responsibleParty":14,"collaborators":7,"id":16,"slug":7,"hasResults":17,"nctId":18,"briefTitle":19,"officialTitle":19,"acronym":7,"eligibilityCriteria":20,"healthyVolunteers":17,"sex":21,"minAge":22,"maxAge":23,"enrollmentInfo":24,"targetDuration":27,"studyType":28,"phases":7,"briefSummary":29,"conditions":30,"keywords":34,"overallStatus":37,"whyStopped":7,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":7},{"fullName":5,"class":6},"The First Hospital of Jilin University","OTHER",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"zhentong wei, doctor","CONTACT","15804300686","zhentongwei2009@163.com",{"type":15,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100540317",false,"NCT06315270","To Explore the Feasibility of Dynamic Changes of TCR Diversity in Peripheral Blood in Monitoring Recurrence and Evaluating Prognosis of Epithelial Ovarian Cancer","Inclusion Criteria:\n\n* Newly diagnosed patients with advanced EOC, 18-75 years of age: including patients with preoperative assessment of stage III-IV EOC, who underwent initial tumour cytoreduction and 6-8 courses of postoperative chemotherapy with paclitaxel + carboplatin\u002Fdocetaxel + carboplatin;\n* Eastern Cooperative Oncology Group (ECOG) physical strength status (PS) score of 0 or 1;\n* Cooperation in the treatment process by providing clinicopathological data and imaging data required for the study process;\n* Cooperate with follow-up visits and collection of node blood for clinical efficacy assessment, and agree to use the test data for subsequent research and product development.\n* The initial and follow-up treatment processes are in accordance with NCCN guidelines;\n\nExclusion Criteria:\n\n* Neoadjuvant chemotherapy patients;\n* Splenectomy patients;\n* Patients with contraindications to radiotherapy;\n* Any other patients who, in the judgement of the investigator, may have poor compliance with the procedures and requirements of the study;\n* Unacceptable or unavailable means of assessing specified efficacy such as imaging;\n* Vaccination within 2 months; antibiotics for infection within 2 weeks; history of blood transfusion within 2 weeks;\n* Long-term use of recombinant human erythropoietin, recombinant human interleukin, Ricodin tablets and other drugs affecting the composition of blood cells;\n* Severe organ dysfunction;\n* Infectious diseases such as immunodeficiency syndrome, active tuberculosis, HIV infection, and other infectious diseases not suitable for participation;\n* Pre-cancerous diseases of the blood, such as myelodysplastic syndromes;\n* Have received immunosuppressive therapy within 2 weeks;\n* Suffering from blood clotting disorders.","FEMALE","18 Years","75 Years",{"count":25,"type":26},100,"ESTIMATED","5 Years","OBSERVATIONAL","This project proposes to elucidate the functional impact of T cells in cancer progression and treatment through a comprehensive TCR profiling study and a longitudinal cohort study in patients with advanced epithelial ovarian cancer. Our findings aim to provide clinical insights for monitoring treatment response in a non-invasive way and demonstrate the association of TCR diversity with clinical outcomes and the potential role of TCR profiling in cancer prognosis.",[31,32,33],"Epithelial Ovarian Cancer","Stage III Ovarian Cancer","Stage IV Ovarian Cancer",[35,36],"TCR","Immunological monitoring","NOT_YET_RECRUITING","2024-03-29",{"date":40,"type":41},"2024-04-01","ACTUAL",{"date":43,"type":26},"2024-03-20",{"date":45,"type":26},"2029-03-20",{"name":5,"class":6}]